Dupont Jakob 4

4 · Bolt Biotherapeutics, Inc. · Filed Dec 16, 2025

Form 4

Period: 2025-12-12

Director

Transactions

Award
Director Stock Option (Right to Buy)
2025-12-12+2,500→ 2,500 total
Exercise: $5.44Exp: 2034-09-02→ Common Stock (2,500 underlying)
Disposition to Issuer
Director Stock Option (Right to Buy)
2025-12-12−2,500→ 0 total
Exercise: $13.60Exp: 2034-09-02→ Common Stock (2,500 underlying)
Award
Director Stock Option (Right to Buy)
2025-12-12+849→ 849 total
Exercise: $5.44Exp: 2034-09-02→ Common Stock (849 underlying)
Disposition to Issuer
Director Stock Option (Right to Buy)
2025-12-12−849→ 0 total
Exercise: $13.60Exp: 2034-09-02→ Common Stock (849 underlying)
Award
Director Stock Option (Right to Buy)
2025-12-12+1,000→ 1,000 total
Exercise: $5.44Exp: 2035-04-30→ Common Stock (1,000 underlying)
Disposition to Issuer
Director Stock Option (Right to Buy)
2025-12-12−1,000→ 0 total
Exercise: $7.02Exp: 2035-04-30→ Common Stock (1,000 underlying)
Award
Director Stock Option (Right to Buy)
2025-12-12+1,100→ 1,100 total
Exercise: $5.44Exp: 2035-05-26→ Common Stock (1,100 underlying)
Disposition to Issuer
Director Stock Option (Right to Buy)
2025-12-12−1,100→ 0 total
Exercise: $6.40Exp: 2035-05-26→ Common Stock (1,100 underlying)

Footnotes (7)

[F1]For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the shares will vest upon the Reporting Person completing each month of continuous service following September 3, 2024; provided, however that the option will vest in full upon a change in control.
[F2]The reporting person agreed to cancellation of an option granted on September 3, 2024, in exchange for a new option having a lower exercise price.
[F3]The option is fully vested and exercisable.
[F4]The reporting person agreed to cancellation of an option granted on September 3, 2024, in exchange for a new option having a lower exercise price.
[F5]The reporting person agreed to cancellation of an option granted on May 1, 2025, in exchange for a new option having a lower exercise price.
[F6]The shares subject to the option will vest on the earlier of May 27, 2026 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer.
[F7]The reporting person agreed to cancellation of an option granted on May 27, 2025, in exchange for a new option having a lower exercise price.

Documents

1 file